Published in J Clin Endocrinol Metab on February 01, 2009
Update in vitamin D. J Clin Endocrinol Metab (2010) 4.48
Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab (2009) 3.81
Vitamin D, parathyroid hormone, and cardiovascular events among older adults. J Am Coll Cardiol (2011) 2.56
Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res (2011) 2.30
Measurement uncertainty of 25-OH vitamin D determination with different commercially available kits: impact on the clinical cut offs. Osteoporos Int (2009) 1.47
Primary hyperparathyroidism: Update on presentation, diagnosis, and management in primary care. Can Fam Physician (2011) 1.28
Multiple endocrine neoplasia type 1 knockout mice develop parathyroid, pancreatic, pituitary and adrenal tumours with hypercalcaemia, hypophosphataemia and hypercorticosteronaemia. Endocr Relat Cancer (2009) 1.21
Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity. J Clin Endocrinol Metab (2010) 1.21
Renal manifestations of primary hyperparathyroidism. Indian J Endocrinol Metab (2012) 1.06
Primary hyperparathyroidism: an overview. Int J Endocrinol (2011) 1.06
24-hour urinary calcium in primary hyperparathyroidism. Clin Med Res (2013) 1.03
Association of 25-hydroxyvitamin D and parathyroid hormone with incident hypertension: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol (2014) 1.01
Asymptomatic primary hyperparathyroidism. J Clin Densitom (2013) 0.96
Relation of vitamin D and parathyroid hormone to cardiac biomarkers and to left ventricular mass (from the Cardiovascular Health Study). Am J Cardiol (2012) 0.94
Serum vitamin D and parathyroid hormone in relation to cardiac structure and function: the ICELAND-MI substudy of AGES-Reykjavik. J Clin Endocrinol Metab (2013) 0.94
Parathyroid hormone concentration and risk of cardiovascular diseases: the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J (2014) 0.92
Vitamin D insufficiency defined by serum 25-hydroxyvitamin D and parathyroid hormone before and after oral vitamin D₃ load in Japanese subjects. J Bone Miner Metab (2010) 0.89
Circulating Vitamin D Levels and Risk of Colorectal Cancer in Women. Cancer Prev Res (Phila) (2015) 0.88
Predictors of renal function in primary hyperparathyroidism. J Clin Endocrinol Metab (2014) 0.88
Asymptomatic primary hyperparathyroidism: a commentary on the revised guidelines. Endocr Pract (2009) 0.87
Vitamin D in Primary Hyperparathyroidism: Effects on Clinical, Biochemical, and Densitometric Presentation. J Clin Endocrinol Metab (2015) 0.87
Aldosterone, parathyroid hormone, and the use of renin-angiotensin-aldosterone system inhibitors: the multi-ethnic study of atherosclerosis. J Clin Endocrinol Metab (2014) 0.87
Variation in parathyroid hormone immunoassay results--a critical governance issue in the management of chronic kidney disease. Nephrol Dial Transplant (2011) 0.86
Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial. BMC Endocr Disord (2012) 0.83
Surgical management of normocalcemic primary hyperparathyroidism. World J Surg (2012) 0.83
Low vitamin D levels have become less common in primary hyperparathyroidism. Osteoporos Int (2015) 0.83
Total parathyroidectomy in a large cohort of cases with hyperparathyroidism associated with multiple endocrine neoplasia type 1: experience from a single academic center. Clinics (Sao Paulo) (2012) 0.81
Diagnosis and management of primary hyperparathyroidism in Europe. QJM (2012) 0.81
Association between serum 25-hydroxyvitamin D level and subclinical cardiovascular disease in primary hyperparathyroidism. J Clin Endocrinol Metab (2013) 0.81
Primary Hyperparathyroidism: A Tale of Two Cities Revisited - New York and Shanghai. Bone Res (2013) 0.81
BMD improvements after operation for primary hyperparathyroidism. Langenbecks Arch Surg (2012) 0.80
Severe metabolic bone disease in pregnancy mimicking malignancy. CMAJ (2014) 0.80
Biochemical markers for assessment of calcium economy and bone metabolism: application in clinical trials from pharmaceutical agents to nutritional products. Nutr Res Rev (2014) 0.80
Effect of parathyroidectomy versus risedronate on volumetric bone mineral density and bone geometry at the tibia in postmenopausal women with primary hyperparathyroidism. J Bone Miner Metab (2013) 0.80
Prevalence of primary hyperparathyroidism and impact on bone mineral density in elderly men: MrOs Sweden. World J Surg (2011) 0.79
Alendronate therapy in men with primary hyperparathyroidism. Endocr Pract (2010) 0.79
PTH Assays: Understanding What We Have and Forecasting What We Will Have. J Osteoporos (2012) 0.79
Primary hyperparathyroidism. CMAJ (2011) 0.79
Primary hyperparathyroidism and celiac disease: a population-based cohort study. J Clin Endocrinol Metab (2012) 0.78
Post-surgical follow-up of primary hyperparathyroidism associated with multiple endocrine neoplasia type 1. Clinics (Sao Paulo) (2012) 0.78
Mild primary hyperparathyroidism: a literature review. Oncologist (2014) 0.76
Parathyroid hormone is associated with incident diabetes in white, but not black adults: The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Metab (2016) 0.75
Evidence based solving approach in diagnosis of primary hyperparathyroidism with oral manifestations: report of three unusual cases. J Lab Physicians (2013) 0.75
Parathyroid hormone and the risk of incident hypertension: the Atherosclerosis Risk in Communities study. J Hypertens (2016) 0.75
Reduction of Parathyroid Hormone with Vitamin D Supplementation in Blacks: A Randomized Controlled Trial. BMC Nutr (2015) 0.75
The Biochemical Profile of Familial Hypocalciuric Hypercalcemia and Primary Hyperparathyroidism during Pregnancy and Lactation: Two Case Reports and Review of the Literature. Case Rep Endocrinol (2016) 0.75
Advances in the management of asymptomatic hyperparathyroidism. F1000 Med Rep (2009) 0.75
Intensive insulin therapy in critically ill patients. N Engl J Med (2001) 40.00
Differentiation of receptor systems activated by sympathomimetic amines. Nature (1967) 11.46
Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab (2004) 8.36
A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature (1991) 7.98
Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science (1997) 7.95
Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study. Stroke (1996) 7.81
Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell (1992) 7.61
A microagglutination technique for detection and measurement of rickettsial antibodies. Acta Virol (1969) 7.17
An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Methods (2001) 6.68
The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int (2007) 6.44
Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J Biol Chem (1995) 6.25
Risk of new vertebral fracture in the year following a fracture. JAMA (2001) 6.17
Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab (2001) 6.12
Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature (1994) 5.34
Physical interaction of the retinoblastoma protein with human D cyclins. Cell (1993) 5.31
The hypocalciuric or benign variant of familial hypercalcemia: clinical and biochemical features in fifteen kindreds. Medicine (Baltimore) (1981) 5.29
Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int (2014) 5.17
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int (2000) 4.85
Mutations in the human Ca(2+)-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell (1993) 4.13
Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. Am J Med (1997) 3.91
Canadian normative data for the SF-36 health survey. Canadian Multicentre Osteoporosis Study Research Group. CMAJ (2000) 3.77
Vitamin D and diabetes. Diabetologia (2005) 3.58
Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet (1994) 3.51
A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int (2007) 3.50
A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. N Engl J Med (1996) 3.20
A mouse model of human familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Nat Genet (1995) 3.18
Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell (1999) 3.16
A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med (2000) 3.16
Influence of the vitamin D-binding protein on the serum concentration of 1,25-dihydroxyvitamin D3. Significance of the free 1,25-dihydroxyvitamin D3 concentration. J Clin Invest (1981) 3.15
Calcium supplementation and increases in bone mineral density in children. N Engl J Med (1992) 3.13
HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet (2002) 3.07
Adipocyte tissue volume in bone marrow is increased with aging and in patients with osteoporosis. Biogerontology (2001) 3.00
Immunoglobulin-gene rearrangements as unique clonal markers in human lymphoid neoplasms. N Engl J Med (1983) 2.96
Importance of heart failure with preserved systolic function in patients > or = 65 years of age. CHS Research Group. Cardiovascular Health Study. Am J Cardiol (2001) 2.93
Immunoglobulin gene rearrangement and cell surface antigen expression in acute lymphocytic leukemias of T cell and B cell precursor origins. J Clin Invest (1983) 2.91
Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers. J Bone Miner Res (2001) 2.89
Function of a human cyclin gene as an oncogene. Proc Natl Acad Sci U S A (1994) 2.87
Analytical and clinical validation of the 25 OH vitamin D assay for the LIAISON automated analyzer. Clin Biochem (2004) 2.78
Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I. Thorax (2003) 2.68
Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies. N Engl J Med (1990) 2.67
A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proc Natl Acad Sci U S A (2001) 2.57
Papillary thyroid carcinoma associated with papillary renal neoplasia: genetic linkage analysis of a distinct heritable tumor syndrome. J Clin Endocrinol Metab (2000) 2.52
Increased mortality in patients with a hip fracture-effect of pre-morbid conditions and post-fracture complications. Osteoporos Int (2007) 2.46
Blood glucose measurements during symptomatic episodes in patients with suspected postprandial hypoglycemia. N Engl J Med (1989) 2.45
Interpretation and use of FRAX in clinical practice. Osteoporos Int (2011) 2.43
Duodenal calcium absorption in vitamin D receptor-knockout mice: functional and molecular aspects. Proc Natl Acad Sci U S A (2001) 2.42
CSF soluble amyloid precursor proteins in the diagnosis of incipient Alzheimer disease. Neurology (2011) 2.41
Estimation of the prevalence of low bone density in Canadian women and men using a population-specific DXA reference standard: the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int (2000) 2.40
Menin, the product of the MEN1 gene, is a nuclear protein. Proc Natl Acad Sci U S A (1998) 2.39
Relation between serum and urinary calcium with particular reference to parathyroid activity. Lancet (1969) 2.33
Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab (1996) 2.33
Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int (2006) 2.33
The influence of osteoporotic fractures on health-related quality of life in community-dwelling men and women across Canada. Osteoporos Int (2001) 2.32
Limits of rickettsial infectivity. Infect Immun (1978) 2.31
Targeted ablation of the 25-hydroxyvitamin D 1alpha -hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction. Proc Natl Acad Sci U S A (2001) 2.30
The use of real-time reverse transcriptase PCR for the quantification of cytokine gene expression. J Biomol Tech (2003) 2.30
Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project. J Bone Joint Surg Am (2013) 2.29
Plasma concentrations of 25-hydroxy-vitamin D and 1,25-dihydroxy-vitamin D are related to the phenotype of Gc (vitamin D-binding protein): a cross-sectional study on 595 early postmenopausal women. Calcif Tissue Int (2005) 2.23
Autosomal dominant hypocalcaemia caused by a Ca(2+)-sensing receptor gene mutation. Nat Genet (1994) 2.23
Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (1993) 2.22
D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. Oncogene (1991) 2.21
Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J (2007) 2.17
Polycystin-L is a calcium-regulated cation channel permeable to calcium ions. Nature (1999) 2.17
Molecular cloning and characterization of a channel-like transporter mediating intestinal calcium absorption. J Biol Chem (1999) 2.16
Clonal rat parathyroid cell line expresses a parathyroid hormone-related peptide but not parathyroid hormone itself. Biochem Biophys Res Commun (1989) 2.15
Resistance to multiple hormones in patients with pseudohypoparathyroidism. Association with deficient activity of guanine nucleotide regulatory protein. Am J Med (1983) 2.14
Q fever endocarditis in the United States. Ann Intern Med (1979) 2.12
Expression of an extracellular calcium-sensing receptor in human and mouse bone marrow cells. J Bone Miner Res (1997) 2.11
Osteoporosis in lung transplantation candidates with end-stage pulmonary disease. Am J Med (1996) 2.08
Fracture rates and risk factors for fractures in patients with spinal cord injury. Spinal Cord (1998) 2.07
Induction of formation of presynaptic terminals in neuroblastoma cells by synapsin IIb. Nature (1991) 2.06
PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma. Proc Natl Acad Sci U S A (1991) 2.04
L-amino acid sensing by the extracellular Ca2+-sensing receptor. Proc Natl Acad Sci U S A (2000) 2.02
Patterns of failure following loco-regional radiotherapy in the treatment of limited stage small cell lung cancer. Int J Radiat Oncol Biol Phys (1994) 2.01
Parathyroid hormone-related peptide-depleted mice show abnormal epiphyseal cartilage development and altered endochondral bone formation. J Cell Biol (1994) 2.00
Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab (2000) 2.00
Dimerization of the extracellular calcium-sensing receptor (CaR) on the cell surface of CaR-transfected HEK293 cells. J Biol Chem (1998) 1.98
Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int (1999) 1.98
Loss of the retinoblastoma tumor-suppressor gene in parathyroid carcinoma. N Engl J Med (1994) 1.97
Quality of life in stage II breast cancer: an instrument for clinical trials. J Clin Oncol (1988) 1.93
Clinical clues to the cause of Addison's disease. Am J Med (1985) 1.91
Somatic mutation of the MEN1 gene in parathyroid tumours. Nat Genet (1997) 1.90
Inactivation of menin, a Smad3-interacting protein, blocks transforming growth factor type beta signaling. Proc Natl Acad Sci U S A (2001) 1.88
Cyclin D and oncogenesis. Curr Opin Genet Dev (1993) 1.88
Activity products in stone-forming and non-stone-forming urine. Clin Sci (1968) 1.87
Thyroid function in patients with hyperemesis gravidarum. Am J Obstet Gynecol (1982) 1.87
Molecular cloning and functional expression of human parathyroid calcium receptor cDNAs. J Biol Chem (1995) 1.86
The impact of incident fractures on health-related quality of life: 5 years of data from the Canadian Multicentre Osteoporosis Study. Osteoporos Int (2008) 1.86
Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas. Cancer Res (1997) 1.82
A transcript map for the 2.8-Mb region containing the multiple endocrine neoplasia type 1 locus. Genome Res (1997) 1.82
Osteoporosis and low bone mass in premenopausal and perimenopausal women. Endocr Pract (2001) 1.81
Parathyroid glands: combination of (99m)Tc MIBI scintigraphy and US for demonstration of parathyroid glands and nodules. Radiology (2000) 1.80
Immunoglobulin responses in acute Q fever. J Clin Microbiol (1985) 1.80
Vitamin D-binding protein (Gc-globulin) binds actin. J Biol Chem (1980) 1.80
Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk--a meta-analysis. Osteoporos Int (2006) 1.79
Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia (2005) 1.79
The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation. Endocr Rev (1999) 1.78
Global vitamin D levels in relation to age, gender, skin pigmentation and latitude: an ecologic meta-regression analysis. Osteoporos Int (2008) 1.78